The primary objective of this trial is to evaluate the long-term safety and efficacy of the NOVA intracranial drug-eluting stent system in "real world" patients with intracranial atherosclerotic stenosis.
Males or females between 18 and 80 years of age;
Symptomatic intracranial arteriosclerosis stenosis with reference diameter 2.25-4.00mm;
intracranial artery stenosis ( ≥70%) conformed by digital subtraction angiography (DSA);
Those who voluntarily participate in the study and sign informed consent form.
Those who have surgery within previous 30 days or plan to perform major surgery in the next 90 days (surgery grade 3 and above);
Subjects of acute hemorrhagic stroke within 3 months;
The baseline mRS of disabling stroke is more than 3;
The target vessel is severely calcified and closely related to stenosis;
Sino Medical Sciences Technology Inc.
Lead sponsor